Dosages of Emactuzumab for TGCT Treatment, SYNOX Therapeutics
Summary
The USPTO published patent application US20260098087A1 by SYNOX Therapeutics UK Limited covering dosage regimens of emactuzumab, an anti-CSF-1R antibody, for treating tenosynovial giant cell tumour (TGCT). The application, filed October 20, 2025, describes treatment regimes and methods using the colony stimulating factor-1 receptor-binding antibody. The application is now publicly available as part of the standard patent examination process.
What changed
The USPTO published patent application US20260098087A1 for SYNOX Therapeutics UK Limited, disclosing dosage and administration protocols for emactuzumab in treating tenosynovial giant cell tumour (TGCT). The patent covers treatment regimes using an antibody or antigen-binding fragment that specifically binds colony stimulating factor-1 receptor (CSF-1R).
For pharmaceutical and biotech companies, this publication indicates SYNOX's positioning in the TGCT therapeutic space and CSF-1R antibody development. Competitors researching similar targets should monitor this application's prosecution for potential claim scope that may affect freedom to operate.
What to do next
- Monitor for updates
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DOSAGES OF EMACTUZUMAB
Application US20260098087A1 Kind: A1 Apr 09, 2026
Assignee
SYNOX THERAPEUTICS UK LIMITED
Inventors
Raymond BARLOW, Axel MESCHEDER, Michael CANNARILE, Georgina MENESES-LORENTE
Abstract
The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.
CPC Classifications
C07K 16/28 A61K 9/0019 A61P 35/00 A61K 2039/545
Filing Date
2025-10-20
Application No.
19363068
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.